Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, Toedling J, Merz C, Lesche R, Kamburov A, Siebeneicher H, Bauser M, Hägebarth A.

Mol Cancer Ther. 2018 Nov;17(11):2285-2296. doi: 10.1158/1535-7163.MCT-17-1253. Epub 2018 Aug 16.

PMID:
30115664
2.

Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.

Rossi S, Castello A, Toschi L, Lopci E.

Immunotherapy. 2018 Jul;10(9):797-805. doi: 10.2217/imt-2017-0187.

PMID:
30008262
3.

Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer.

Castello A, Grizzi F, Toschi L, Rossi S, Rahal D, Marchesi F, Russo C, Finocchiaro G, Lopci E.

Nucl Med Commun. 2018 Jul;39(7):636-644. doi: 10.1097/MNM.0000000000000832.

PMID:
29608508
4.

Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?

Rossi S, Finocchiaro G, Marchetti S, Toschi L, Santoro A.

Immunotherapy. 2018 Apr;10(5):403-410. doi: 10.2217/imt-2017-0151.

PMID:
29473467
5.

Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.

Toschi L, Rossi S, Finocchiaro G, Santoro A.

Ecancermedicalscience. 2017 Nov 30;11:787. doi: 10.3332/ecancer.2017.787. eCollection 2017. Review.

6.

Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.

Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E.

Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325. doi: 10.1007/s00259-017-3802-5. Epub 2017 Aug 16. Review.

PMID:
28815334
7.

Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT: a pilot study on semiquantitative and computer-aided fractal geometry analysis.

Lopci E, Grizzi F, Russo C, Toschi L, Grassi I, Cicoria G, Lodi F, Mattioli S, Fanti S.

Nucl Med Commun. 2017 Apr;38(4):340-346. doi: 10.1097/MNM.0000000000000656.

PMID:
28263239
8.

Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation.

Pessina F, Navarria P, Cozzi L, Tomatis S, Ascolese AM, Franzese C, Toschi L, Santoro A, De Rose F, Franceschini D, Bello L, Scorsetti M.

Br J Radiol. 2017 Apr;90(1072):20170022. doi: 10.1259/bjr.20170022. Epub 2017 Mar 3.

9.

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, Kaulfuss S, Panknin O, Zimmermann K, Toschi L, Neuhaus R, Haegebarth A, Rehwinkel H, Hess-Stumpp H, Bauser M, Bochtler T, Struys EA, Sharma A, Bakkali A, Geffers R, Araujo-Cruz MM, Thol F, Gabdoulline R, Ganser A, Ho AD, von Deimling A, Rippe K, Heuser M, Krämer A.

Leukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46. Epub 2017 Jan 31.

10.

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, Sahm F, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Panknin O, Rehwinkel H, Zimmermann K, Hillig RC, Guenther J, Toschi L, Neuhaus R, Haegebart A, Hess-Stumpp H, Bauser M, Wick W, Unterberg A, Herold-Mende C, Platten M, von Deimling A.

Acta Neuropathol. 2017 Apr;133(4):629-644. doi: 10.1007/s00401-017-1677-y. Epub 2017 Jan 25.

PMID:
28124097
11.

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.

PMID:
27251642
12.

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.

Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, Sidoni A, Mountzios G, Crinò L, Bellezza G, Rebonato A, Ferolla P, Toschi L.

Lung Cancer. 2016 May;95:82-7. doi: 10.1016/j.lungcan.2016.03.006. Epub 2016 Mar 15.

PMID:
27040856
13.

Effect of oncogene activating mutations and kinase inhibitors on amino acid metabolism of human isogenic breast cancer cells.

Kim ES, Samanta A, Cheng HS, Ding Z, Han W, Toschi L, Chang YT.

Mol Biosyst. 2015 Dec;11(12):3378-86. doi: 10.1039/c5mb00525f.

PMID:
26469267
14.

Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.

De Rose F, Cozzi L, Navarria P, Ascolese AM, Clerici E, Infante M, Alloisio M, Testori A, Toschi L, Finocchiaro G, Santoro A, Scorsetti M.

Clin Oncol (R Coll Radiol). 2016 Jan;28(1):13-20. doi: 10.1016/j.clon.2015.08.011. Epub 2015 Sep 15.

PMID:
26385822
15.

Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

Finocchiaro G, Toschi L, Gianoncelli L, Baretti M, Santoro A.

Ann Transl Med. 2015 Apr;3(6):83. doi: 10.3978/j.issn.2305-5839.2015.03.43. Review.

16.

Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography.

Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

Am J Respir Crit Care Med. 2015 May 15;191(10):1166-75. doi: 10.1164/rccm.201408-1475OC.

PMID:
25760561
17.

PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, Fonti C, Lodi F, Mattioli S, Fanti S.

Am J Nucl Med Mol Imaging. 2014 Jun 7;4(4):365-84. eCollection 2014. Review.

18.

Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.

Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, Perrino M, Siracusano L, Di Tommaso L, Infante M, Alloisio M, Roncalli M, Scorsetti M, Jänne PA, Santoro A, Varella-Garcia M.

PLoS One. 2014 Apr 15;9(4):e95303. doi: 10.1371/journal.pone.0095303. eCollection 2014.

19.

Isogenic human mammary epithelial cell lines: novel tools for target identification and validation. Comprehensive characterization of an isogenic human mammary epithelial cell model provides evidence for epithelial-mesenchymal transition.

Ulbricht U, Sommer A, Beckmann G, Lutzenberger M, Seidel H, Kreft B, Toschi L.

Breast Cancer Res Treat. 2013 Apr;138(2):437-56. doi: 10.1007/s10549-013-2472-7. Epub 2013 Mar 13.

PMID:
23483306
20.

Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism.

Koglin N, Mueller A, Berndt M, Schmitt-Willich H, Toschi L, Stephens AW, Gekeler V, Friebe M, Dinkelborg LM.

Clin Cancer Res. 2011 Sep 15;17(18):6000-11. doi: 10.1158/1078-0432.CCR-11-0687. Epub 2011 Jul 12.

21.

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z.

Genome Med. 2010 Aug 11;2(8):53. doi: 10.1186/gm174.

22.

Impact of biomarkers on non-small cell lung cancer treatment.

Toschi L, Cappuzzo F.

Target Oncol. 2010 Mar;5(1):5-17. doi: 10.1007/s11523-010-0132-y. Epub 2010 May 5. Review.

PMID:
20443070
23.

Clinical implications of MET gene copy number in lung cancer.

Toschi L, Cappuzzo F.

Future Oncol. 2010 Feb;6(2):239-47. doi: 10.2217/fon.09.164. Review.

PMID:
20146583
24.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.

Cancer Cell. 2010 Jan 19;17(1):77-88. doi: 10.1016/j.ccr.2009.11.022.

25.

Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.

Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA, Santoro A.

Ann Oncol. 2010 Mar;21(3):562-7. doi: 10.1093/annonc/mdp357. Epub 2009 Sep 18.

26.

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M.

J Clin Oncol. 2009 Apr 1;27(10):1667-74. doi: 10.1200/JCO.2008.19.1635. Epub 2009 Mar 2.

27.

Gemcitabine for the treatment of advanced nonsmall cell lung cancer.

Toschi L, Cappuzzo F.

Onco Targets Ther. 2009 Feb 18;2:209-17.

28.

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.

Xu JM, Han Y, Duan HQ, Gao EM, Zhang Y, Liu XQ, Zhang JS, Toschi L, Galetta D, Azzariti A, Paradiso A.

J Cancer Res Clin Oncol. 2009 Jun;135(6):771-82. doi: 10.1007/s00432-008-0512-1. Epub 2008 Nov 20.

PMID:
19020901
29.

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Cappuzzo F, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M.

Ann Oncol. 2009 Feb;20(2):298-304. doi: 10.1093/annonc/mdn635. Epub 2008 Oct 3.

30.

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.

Toschi L, Jänne PA.

Clin Cancer Res. 2008 Oct 1;14(19):5941-6. doi: 10.1158/1078-0432.CCR-08-0071. Review.

31.

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA.

Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24.

32.

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F.

Rev Recent Clin Trials. 2006 Jan;1(1):1-13. Review.

PMID:
18393776
33.

EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?

Finocchiaro G, Toschi L, Garassino I, De Vincenzo F, Campagnoli E, Zucali P, Cavina R, Ceresoli GL, Santoro A, Cappuzzo F.

Expert Opin Med Diagn. 2007 Oct;1(2):183-91. doi: 10.1517/17530059.1.2.183.

PMID:
23489305
34.

Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer.

Toschi L, Cappuzzo F, Jänne PA.

Ann Oncol. 2007 Jul;18 Suppl 9:ix150-5. Review. No abstract available.

PMID:
17631569
35.

Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.

Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M.

J Clin Oncol. 2007 Jun 1;25(16):2248-55.

PMID:
17538169
36.

Is gemcitabine cost effective in cancer treatment?

Toschi L, Finocchiaro G, Ceresoli GL, Zucali PA, Cavina R, Garassino I, De Vincenzo F, Santoro A, Cappuzzo F.

Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):239-49. doi: 10.1586/14737167.7.3.239.

PMID:
20528311
37.

Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges.

Cappuzzo F, Toschi L, Finocchiaro G, Ligorio C, Santoro A.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S10-23. Review.

PMID:
17520577
38.

EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Cappuzzo F, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Hirsch FR, Crino L, Varella-Garcia M.

J Thorac Oncol. 2007 May;2(5):423-9. Erratum in: J Thorac Oncol. 2007 Jul;2(7):676. Ligorio, Claudio [corrected to Ligorio, Claudia].

39.
40.

Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges.

Cappuzzo F, Toschi L, Finocchiaro G, Ligorio C, Santoro A.

Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):10-23. doi: 10.5301/JBM.2008.5699.

PMID:
28207110
41.

Protein-structure-based prediction of animal model suitability for pharmacodynamic studies of subtype-selective estrogens.

Toschi L, Hilbig J, Wintermantel T, Engelhaupt A, Walter A, Fritzemeier KH, Hillisch A.

ChemMedChem. 2006 Nov;1(11):1237-48.

PMID:
17001712
42.

Development of gemcitabine in non-small cell lung cancer: the Italian contribution.

Metro G, Cappuzzo F, Finocchiaro G, Toschi L, Crinò L.

Ann Oncol. 2006 May;17 Suppl 5:v37-46. Review.

PMID:
16807461
43.

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.

Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR.

Ann Oncol. 2006 Jul;17(7):1120-7. Epub 2006 Apr 6.

PMID:
16600976
44.

Role of gemcitabine in cancer therapy.

Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F.

Future Oncol. 2005 Feb;1(1):7-17. Review.

PMID:
16555971
45.

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.

Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA Jr, Hirsch FR, Varella-Garcia M.

Br J Cancer. 2005 Dec 12;93(12):1334-40.

46.

LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain.

Korr D, Toschi L, Donner P, Pohlenz HD, Kreft B, Weiss B.

Cell Signal. 2006 Jun;18(6):910-20. Epub 2005 Oct 21.

PMID:
16243488
47.

Perspectives on salvage therapy for non-small-cell lung cancer.

Cappuzzo F, Finocchiaro G, Trisolini R, Toschi L, Bartolini S, Metro G, Crinò L.

Oncology (Williston Park). 2005 Jul;19(8):989-95; discussion 995-6, 999, 1003-4, passim. Review.

48.

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR.

J Clin Oncol. 2005 Aug 1;23(22):5007-18.

PMID:
16051952
49.

Allelic loss on chromosomes 2q21 and 19p 13.2 in oxyphilic thyroid tumors.

Stankov K, Pastore A, Toschi L, McKay J, Lesueur F, Kraimps JL, Bonneau D, Gibelin H, Levillain P, Volante M, Papotti M, Romeo G.

Int J Cancer. 2004 Sep 1;111(3):463-7.

50.

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).

Cappuzzo F, Bartolini S, Ceresoli GL, Tamberi S, Spreafico A, Lombardo L, Gregorc V, Toschi L, Calandri C, Villa E, Crinò L.

Br J Cancer. 2004 Jan 12;90(1):82-6.

Supplemental Content

Loading ...
Support Center